US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
2.670
-0.060 (-2.20%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
July 04, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
July 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
July 03, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Forecasting The Future: 5 Analyst Projections For Altimmune
↗
June 21, 2024
Via
Benzinga
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via
MarketBeat
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
July 01, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
June 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
↗
June 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
Via
The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
↗
June 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Via
The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 28, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
↗
June 28, 2024
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
Via
InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
June 28, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Why Are Altimmune Shares Trading Lower Wednesday?
↗
June 26, 2024
Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's Chief Financial Officer.
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
June 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
June 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 24, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
↗
June 24, 2024
Alimera Sciences stock is up on Monday as investors react to a $5.50 per share acquisition offer for ALIM from ANI Pharmaceuticals.
Via
InvestorPlace
BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms
↗
June 24, 2024
Bitfarms stock is down on Monday after Riot Platforms withdrew its offer for BITF stock in favor of nominating new board memebers.
Via
InvestorPlace
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
↗
June 24, 2024
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.
Via
InvestorPlace
Altimmune Stock Is Rising Monday: What's Driving The Action?
↗
June 24, 2024
Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes...
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
June 24, 2024
Via
Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
June 23, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
June 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
June 21, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
June 21, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
June 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ALTIMMUNE, INC. INVESTORS: Pending Lead Plaintiff Deadline in ALT Securities Fraud Class Action; Stockholders Should Contact Robbins LLP for Information
June 20, 2024
From
Robbins LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
June 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
